How did Clinitech perform in FY26?

The company grew revenue by 15% to ₹9.47 crore. Net profit grew at a slower pace of 5.8%, totaling ₹41.79 lakhs.

What held back profit growth?

Profit growth was constrained by higher operational costs and increased tax expenses during the year.

What is the status of the company's IPO funds?

Clinitech has utilized 91% of its IPO proceeds for diagnostic expansion as originally planned.

Is this a major turning point for the company?

No. These results represent a routine procedural disclosure that confirms the company's current operational trajectory without providing a new valuation catalyst.

Earnings · Hospital & Healthcare · Micro cap

Clinitech Laboratory revenue grows 15% in FY26

The pathology provider hit ₹9.47 crore in revenue, though rising costs kept net profit growth to 5.8%.

— 1 earlier story on Clinitech Laboratory Ltd. →

CTLLAB 28 May 2026 · 3:26 PM IST Verify on BSE · NSE

Mkt cap₹9.22 cr

P/E23.36×

ROE4.47%

Debt / eq.0.00

₹9.47 cr Annual revenue for FY26, representing 15% growth.

What's new

Revenue rose 15% to ₹9.47 crore for FY26.
Net profit reached ₹41.79 lakhs, a 5.8% increase.
The company has deployed 91% of its IPO funds toward diagnostic expansion.

Why this matters

Clinitech is a nano-cap firm maintaining a steady, if modest, growth path. While the expansion of its diagnostic footprint is on track, the margin pressure from rising operational and tax costs limits the bottom-line impact for shareholders.

What we're watching

Whether the company can improve margins in the coming quarters.
The final deployment of the remaining 9% of IPO proceeds.
Any updates on new diagnostic center openings.

The full read

Clinitech Laboratory posted steady results for FY26, with revenue climbing 15% to ₹9.47 crore.

Profitability did not keep pace. While the company successfully deployed 91% of its IPO proceeds toward diagnostic expansion, consolidated net profit rose only 5.8% to ₹41.79 lakhs as higher operational costs and tax expenses eroded the gains. For a nano-cap pathology provider, these figures confirm a stable operational path, but the filing is a routine disclosure that aligns with prior expectations, offering no major surprises or immediate catalysts for the stock.

Questions answered

How did Clinitech perform in FY26?: The company grew revenue by 15% to ₹9.47 crore. Net profit grew at a slower pace of 5.8%, totaling ₹41.79 lakhs.
What held back profit growth?: Profit growth was constrained by higher operational costs and increased tax expenses during the year.
What is the status of the company's IPO funds?: Clinitech has utilized 91% of its IPO proceeds for diagnostic expansion as originally planned.
Is this a major turning point for the company?: No. These results represent a routine procedural disclosure that confirms the company's current operational trajectory without providing a new valuation catalyst.

Mentioned: Clinitech Laboratory Ltd

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CTLLAB →

28 May 2026 · 3:26 PM IST Clinitech Laboratory revenue grows 15% in FY26
today Clinitech Laboratory revenue climbs 15% to ₹9.49 crore in FY26